Junshi Bio proposes share option schemes, gets monkeypox vaccine trial approval

Shanghai Junshi Biosciences Co., Ltd. announced proposed 2025 H share option and A share option incentive schemes, pending shareholder approval. The H share option scheme has a mandate limit of 10% of total issued shares, or 102,587,400 shares, and will grant 13,210,000 H share options to seven executive directors and three other employee participants. The A share option incentive scheme will grant 25,360,000 A shares under the first grant, and 8,000,000 A share options will be conditionally granted to chairman and substantial shareholder Mr. Xiong. Exercise prices are HK$32.30 for H shares and RMB46.67 for A shares, with vesting over two years linked to company-level and individual performance targets, including operating income and net profit reduction ratios.

In a related announcement, Junshi Bio's subsidiary, Shanghai JunTop Biosciences Co., Ltd., received clinical trial approval from the National Medical Products Administration for JT118 injection. This recombinant protein vaccine is intended for the prevention of monkeypox virus infection. The approval follows preclinical studies demonstrating its efficacy and safety profile.